Last €8.59 EUR
Change Today +0.09 / 1.06%
Volume 117.0
ALMDT On Other Exchanges
Symbol
Exchange
EN Paris
As of 6:17 AM 04/17/14 All times are local (Market data is delayed by at least 15 minutes).

median technologies (ALMDT) Snapshot

Open
€8.51
Previous Close
€8.50
Day High
€8.59
Day Low
€8.51
52 Week High
03/12/14 - €9.15
52 Week Low
02/19/14 - €7.42
Market Cap
50.0M
Average Volume 10 Days
177.3
EPS TTM
€-0.58
Shares Outstanding
5.8M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for MEDIAN TECHNOLOGIES (ALMDT)

Related News

No related news articles were found.

median technologies (ALMDT) Related Businessweek News

No Related Businessweek News Found

median technologies (ALMDT) Details

MEDIAN Technologies S.A. provides medical imaging products and integrated services for diagnosing and monitoring cancer patients in routine clinical practice and clinical drug development. It offers lesion management solutions (LMS) for the management of cancerous or suspicious lesions diagnosed in CT scans. The company’s products include MEDIAN CTIS, a change paradigm for image interpretation and management; LMS-Lung/Track, a software application for the evaluation and follow-up of lesions identified in CT images covering the chest; and LMS-Liver, a software application for the initial evaluation and follow-up of liver metastases and other CT images covering the liver. Its products also comprise LMS-Track, which enhances reproducibility of measurements and standardizes radiological results reporting; LMS-RECIST, a module that manages and enables the creation of standardized reports; and LMS-Lung and LMS-Lung/CAD that provides computer aided detection of pulmonary nodules and micro-nodules. MEDIAN Technologies S.A. has strategic partnership with Canon, Inc.; Kuwait Life Science Company; and Quintiles. The company was founded in 2002 and is based in Valbonne, France.

45 Employees
Last Reported Date: 10/10/13
Founded in 2002

median technologies (ALMDT) Top Compensated Officers

No compensation data is available at this time for the top officers at this company.

Executives, Board Directors

median technologies (ALMDT) Key Developments

MEDIAN Technologies Announces EUR 422,000 Phase II Project Award

MEDIAN Technologies announced that it has been selected to provide imaging services in a new phase II clinical trial. The clinical trial is sponsored by a Top 20 pharmaceutical company and is for a highly aggressive cutaneous cancer type. The anticipated amount for the project is $582,000 equivalent to EUR 422,000 for the company. Within the framework of the study, imaging data will be acquired from approximately 50 clinical sites worldwide, with a start date forecasted in second quarter of 2014. The company will provide the whole set of imaging services including independent central review (ICR) services. ICR services will be performed by radiologists using the company’s Lesion Management Solutions (LMS) software. LMS is a comprehensive suite of software modules for the review of images and quantitative assessment of response to therapy in clinical trials. The company LMS provide sponsors with very accurate and reliable imaging data.

MEDIAN Technologies Signs Sales Contract with the University Hospital of Poitiers

MEDIAN Technologies announced it has signed a contract with the Poitiers University Hospital. The contract was concluded in the context of the patient care market, one of the two primary markets where MEDIAN Technologies is positioned and in which the company provides its Lesion Management Solutions LMS. Under this contract, the oncology imaging software application LMS will be primarily deployed in the Radiology Department of the hospital, and will be available on workstations connected to the PACS. MEDIAN LMS is a comprehensive suite of software modules for the review of images and the assessment of response to therapy of cancer patients. MEDIAN LMS will provide radiologists with new means to optimize patient diagnosis and treatment and will complete the catalog of expert imaging applications and tools available to physicians, including oncologists. LMS is a comprehensive suite of software solutions for the assessment of cancer patient response to therapy from medical images. MEDIAN LMS assists radiologists and oncologists to optimize the diagnosis, treatment and the follow-up of cancer patients.

MEDIAN Technologies Signs Contract to Provide Imaging Services in Large Phase I/II Clinical Trial

MEDIAN Technologies announced it has signed a contract with a global top five pharmaceutical company. Within the framework of this contract, MEDIAN will provide imaging services in a large phase I/II clinical trial. The contract amount is approximately EUR 700,000. Within the framework of this clinical trial, imaging data will be acquired from clinical sites based in the US and Asia. Anticipated total enrollment is approximately 300 patients. MEDIAN will supply all imaging services requested for the study. Imaging services will be based on MEDIAN's Lesion Management Solutions (LMS). LMS is a comprehensive suite of software modules for the review of images and quantitative assessment of response to therapy in clinical trials. MEDIAN's LMS provides sponsors with very accurate and reliable imaging data.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
ALMDT:FP €8.59 EUR +0.09

ALMDT Competitors

Market data is delayed at least 15 minutes.

Company Last Change
MGT Capital Investments Inc $1.98 USD +0.08
View Industry Companies
 

Industry Analysis

ALMDT

Industry Average

Valuation ALMDT Industry Range
Price/Earnings -- Not Meaningful
Price/Sales -- Not Meaningful
Price/Book -- Not Meaningful
Price/Cash Flow NM Not Meaningful
TEV/Sales -- Not Meaningful
 | 

Post a JobJobs

View all jobs

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact MEDIAN TECHNOLOGIES, please visit www.mediantechnologies.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.